Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

DPH 1,269.00 0.00 (0.00%)
price chart
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Today's update from Pagegroup(LSE: PAGE) shows that the global recruitment company endured a somewhat mixed Q2. While its performance in southern Europe and Benelux was impressive with gross profit growth of 25% and 30% respectively, elsewhere ...
Dechra� Pharmaceuticals PLC: Trading Update & Notice of 2016 Annual Results  PR Newswire (press release)
Dechra Pharmaceuticals plc (DPH) Receives Add Rating from Numis Securities Ltd  BBNS
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
OP animal health parent leashes $200M acquisition  Kansas City Business Journal
Numis Reiterated Dechra Pharmaceuticals PLC (LON:DPH) As 'Add'
Following Numis's latest price target of 1320 on the business this highlights that the broker now believes there is an increase of 6.88% from Dechra Pharmaceuticals PLC's current share price of 1235. The number of shares Dechra Pharmaceuticals PLC ...
Risers and fallers, including Premier Oil, Dechra Pharma and Shire  Proactive Investors UK
Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
Pet medicines mammoth Dechra Pharmaceuticals (LSE: DPH) cheered the market with terrific half-year numbers in Monday business, propelling the stock 8% higher from the end of last week.
Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016
"All our business units are performing well, we are in the process of launching several new products, our international expansion plans are progressing as expected and we have made two strategic acquisitions.
Are GlaxoSmithKline plc, Dechra Pharmaceuticals plc & CareTech Holdings plc On ...
For example, Dechra (LSE: DPH) has been able to increase its earnings at a double-digit rate in each of the last three years, with it rising at an annualised rate of 23% during the period.
Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?
While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 ...
Dechra� Pharmaceuticals PLC (Dechra or the Group) : Trading Update
The Board of Dechra Pharmaceuticals PLC (LSE:DPH), issues the following unaudited Trading Update ahead of the Group's half-year financial results for the period ended 31 December 2015, which will be announced on Monday, 22 February 2016.
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
Dechra Pharmaceuticals PLC (LON:DPH) Receives 'Add' Rating From Brokers At Numis
Numis noted a target price of 1285 on Dechra Pharmaceuticals PLC's shares. According to this price target, it now means the analyst believes there is a potential increase of 20.77% from the company's current share price of 1064.
Dechra Pharmaceuticals PLC reiterated as Add By Numis  Fiscal Standard
Numis Securities Ltd Reaffirms "Add" Rating for Dechra ...  The Cerbat Gem